Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Lung nodule detection and potential impact on guideline-based management: a retrospective post-market evaluation of three commercial software systems.

European radiology·2026

Same author

Real-world evidence from a tertiary academic center: clinical characteristics, microbiology and outcomes of oncology patients with febrile neutropenia presenting to the emergency department.

BMC infectious diseases·2026

Same author

HER2-directed therapy is associated with an increased rate of cardiologic emergency department visits in real-world breast cancer patients.

Breast (Edinburgh, Scotland)·2026

Same author

Real-world experience with tabelecleucel within and beyond the approval label.

Blood advances·2026

Same author

Multiomic characterization of small cell lung cancer: Real-world insights into therapeutic opportunities.

Cancer·2026

Same author

Monotherapy With Immune Checkpoint Inhibitors in Patients With Recurrent and/or Metastatic Sinonasal Squamous Cell Carcinoma.

Cancer medicine·2025

Search research articles

Related Experiment Video

Updated: May 21, 2025

Learning Modern Laryngeal Surgery in a Dissection Laboratory

Learning Modern Laryngeal Surgery in a Dissection Laboratory

Published on: March 18, 2020

Systemic therapy for laryngeal carcinoma.

Thorsten Fuereder¹, Florian Kocher², Jan Baptist Vermorken^3,4

¹Department of Medicine I, Medical University of Vienna, Vienna, Austria.

Frontiers in Oncology

|March 19, 2025

Summary

Laryngeal squamous cell carcinoma (LSCC) outcomes remain poor. Novel immunotherapies, especially perioperative regimens, show promise for locally advanced disease, while combinations are explored for recurrent/metastatic LSCC.

Keywords:

head and neck squamous cell carcinoma immunotherapy laryngeal squamous cell carcinoma larynx preservation neoadjuvant

More Related Videos

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Published on: April 20, 2018

Related Experiment Videos

Last Updated: May 21, 2025

Learning Modern Laryngeal Surgery in a Dissection Laboratory

Learning Modern Laryngeal Surgery in a Dissection Laboratory

Published on: March 18, 2020

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Published on: April 20, 2018

Area of Science:

Oncology
Immunotherapy
Head and Neck Cancers

Background:

Laryngeal squamous cell carcinoma (LSCC) causes significant global mortality.
Current multimodal treatments offer limited survival benefits for advanced or recurrent/metastatic LSCC.
Induction chemotherapy has not improved overall survival, despite potential larynx preservation.

Purpose of the Study:

To review recent advancements in immunotherapy for LSCC.
To discuss strategies for improving outcomes in locally advanced and recurrent/metastatic LSCC.
To explore novel therapeutic approaches for overcoming immunotherapy resistance.

Main Methods:

Review of recent clinical trials and research in LSCC immunotherapy.
Analysis of perioperative immunotherapy in the locally advanced setting.
Evaluation of combination strategies for recurrent/metastatic LSCC.

Main Results:

Perioperative immunotherapy demonstrates potential for larynx preservation and improved survival in locally advanced LSCC.
Pembrolizumab-based regimens yield approximately 20% 5-year survival in recurrent/metastatic LSCC.
Significant primary and secondary resistance to immunotherapy is a major challenge.

Conclusions:

Perioperative immunotherapy is a promising strategy for locally advanced LSCC.
Combinatorial approaches involving novel immunotherapies, bispecific antibodies, targeted therapies, and antibody-drug conjugates are crucial for recurrent/metastatic LSCC.
Further research is needed to overcome resistance and enhance quality of life for LSCC patients.